Theseus Pharmaceuticals, Inc. (THRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
THRX Stock Price Chart Interactive Chart >
THRX Price/Volume Stats
| Current price | $12.13 | 52-week high | $15.21 |
| Prev. close | $11.80 | 52-week low | $4.01 |
| Day low | $11.60 | Volume | 95,543 |
| Day high | $12.54 | Avg. volume | 556,883 |
| 50-day MA | $7.29 | Dividend yield | N/A |
| 200-day MA | $7.07 | Market Cap | 469.59M |
Theseus Pharmaceuticals, Inc. (THRX) Company Bio
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest THRX News From Around the Web
Below are the latest news stories about THESEUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate THRX as an investment opportunity.
NMTR and SLRX among healthcare moversGainers: NovoCure NVCR +51%.Zai Lab ZLAB +42%.Theseus Pharmaceuticals (THRX) +12%.Salarius Pharmaceuticals (SLRX) +14%.9 Meters Biopharma (NMTR) +14%.Losers: Nuwellis… |
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development ProgramTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor (TKI) targeting BCR-ABL for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosom |
Theseus Pharmaceuticals Inc. (THRX) Is A Buy Stock For Small Caps – AnalystsTheseus Pharmaceuticals Inc. (NASDAQ:THRX) has seen 0.51 million shares traded in the recent trading session. The company, currently valued at $204.96M, closed the recent trade at $6.04 per share which meant it gained $0.83 on the day or 15.93% during that session. The THRX stock price is -151.82% off its 52-week high price of $15.21 … Theseus Pharmaceuticals Inc. (THRX) Is A Buy Stock For Small Caps – Analysts Read More » |
Have you been able to find a good deal on Theseus Pharmaceuticals Inc.’s shares?Theseus Pharmaceuticals Inc. (NASDAQ:THRX) marked $5.06 per share on Thursday, up from a previous closing price of $4.96. While Theseus Pharmaceuticals Inc. has overperformed by 2.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, THRX fell by -54.37%, with highs and lows ranging from $15.21 to […] |
Investing in These 2 Biotech Stocks Could Double Your Money, Says AnalystLet’s talk about biotech. These stocks present a unique set of attractions for investors, especially investors willing to shoulder some extra risk. To start with, biotech firms have a famously high overhead, and equally long lead-times for product development. But that is balanced by the opportunity for huge gains – sales profits, and share appreciation – when a new drug shows strongly positive clinical trial results, or receives regulatory approval for commercialization. To give an example, jus |
THRX Price Returns
| 1-mo | 144.56% |
| 3-mo | 120.55% |
| 6-mo | 68.24% |
| 1-year | 38.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 143.57% |
| 2022 | -60.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...